Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8107068 | 0.84 | AKR1C1 (0.46) | MAOBCYP2D6AKR1C1 | |
| SCHEMBL8572147 | 0.84 | MAOB (0.49) | MAOBCCR2SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL8105095 | 0.84 | AKR1C1 (0.46) | MAOBCYP2D6AKR1C1 | |
| SCHEMBL12020309 | 0.84 | AKR1C1 (0.46) | MAOBCYP2D6AKR1C1 | |
| SCHEMBL20512694 | 0.82 | KDM4E (0.38) | MAOBCCR2CYP2D6KDM4EMAPK1 | |
| SCHEMBL16859977 | 0.82 | L3MBTL1 (0.50) | KDM4EMAPK1 | |
| SCHEMBL9330568 | 0.81 | AKR1C1 (0.47) | CYP2D6AKR1C1 | |
| SCHEMBL20747777 | 0.81 | ADAM17 (0.52) | HTR2C | |
| SCHEMBL8574804 | 0.81 | MAOB (0.50) | MAOBCCR2SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL15557325 | 0.81 | ADAM17 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493991-B1 | ANTIREFLECTIVE COMPOSITION FOR PHOTORESISTS | MERCK PATENT GMBH (DE) | 2016-03-02 | — | — | EP | claimed |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | MAOB 424/4885CCR2 4476/4885SLC6A2 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.